CN112384282B - 吡咯并[2,3-d]嘧啶化合物的制造方法与中间体及其用途 - Google Patents

吡咯并[2,3-d]嘧啶化合物的制造方法与中间体及其用途 Download PDF

Info

Publication number
CN112384282B
CN112384282B CN201980045496.5A CN201980045496A CN112384282B CN 112384282 B CN112384282 B CN 112384282B CN 201980045496 A CN201980045496 A CN 201980045496A CN 112384282 B CN112384282 B CN 112384282B
Authority
CN
China
Prior art keywords
compound
amino
pyrrolo
methyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980045496.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN112384282A (zh
Inventor
K·K·阿罗拉
J·C·德富里斯特
A·K·希尔斯
B·P·琼斯
K·N·琼斯
C·A·路易斯
A·M·雷恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN112384282A publication Critical patent/CN112384282A/zh
Application granted granted Critical
Publication of CN112384282B publication Critical patent/CN112384282B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CN201980045496.5A 2018-07-06 2019-07-03 吡咯并[2,3-d]嘧啶化合物的制造方法与中间体及其用途 Active CN112384282B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862694698P 2018-07-06 2018-07-06
US62/694698 2018-07-06
US201862776642P 2018-12-07 2018-12-07
US62/776642 2018-12-07
US201962855071P 2019-05-31 2019-05-31
US62/855071 2019-05-31
PCT/IB2019/055683 WO2020008391A1 (en) 2018-07-06 2019-07-03 Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof

Publications (2)

Publication Number Publication Date
CN112384282A CN112384282A (zh) 2021-02-19
CN112384282B true CN112384282B (zh) 2024-07-02

Family

ID=67928862

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980045496.5A Active CN112384282B (zh) 2018-07-06 2019-07-03 吡咯并[2,3-d]嘧啶化合物的制造方法与中间体及其用途

Country Status (15)

Country Link
US (3) US10815240B2 (cg-RX-API-DMAC7.html)
EP (1) EP3817810B1 (cg-RX-API-DMAC7.html)
JP (1) JP7437646B2 (cg-RX-API-DMAC7.html)
KR (1) KR102568464B1 (cg-RX-API-DMAC7.html)
CN (1) CN112384282B (cg-RX-API-DMAC7.html)
AU (1) AU2019299666B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020025701A2 (cg-RX-API-DMAC7.html)
CA (1) CA3105161C (cg-RX-API-DMAC7.html)
ES (1) ES3045115T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251339T1 (cg-RX-API-DMAC7.html)
IL (1) IL279926B2 (cg-RX-API-DMAC7.html)
MX (2) MX2020013896A (cg-RX-API-DMAC7.html)
TW (1) TWI709562B (cg-RX-API-DMAC7.html)
WO (1) WO2020008391A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100196B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3969458A4 (en) 2019-05-13 2023-05-17 Borah, Inc. CHEMICAL COMPOUNDS
CN113637018A (zh) 2020-04-27 2021-11-12 苏州晶云药物科技股份有限公司 磺酰胺类化合物的晶型及其制备方法
CN112279785B (zh) * 2020-10-29 2022-08-16 苏利制药科技江阴有限公司 3,3-二氟环丁胺盐酸盐中间体及其合成方法和3,3-二氟环丁胺盐酸盐合成方法
CN113583992B (zh) * 2021-07-15 2023-06-27 华东理工大学 一种还原胺化酶及其在仲胺合成中的应用
WO2023036289A1 (zh) * 2021-09-10 2023-03-16 上海海和药物研究开发股份有限公司 具有enpp1抑制活性的异羟基肟酸类化合物及其用途
ES2993658B2 (es) 2023-06-27 2025-07-02 Moehs Iberica Sl (3-(metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino)ciclobutilo)carbamato de bencilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de abrocitinib
ES3040374B2 (es) * 2024-04-30 2026-07-09 Moehs Iberica Sl Cocristales de N-{cis-3-[metil(7H-pirrolo[2,3-d]pirimidin-4-il)amino]ciclobutil}propano-1-sulfonamida

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140243312A1 (en) * 2013-02-22 2014-08-28 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives
WO2016024185A1 (en) * 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP4126781B2 (ja) 1998-10-26 2008-07-30 宇部興産株式会社 1−スルホニルピラゾール誘導体及びその製造方法
JP2003005323A (ja) 2001-06-20 2003-01-08 Konica Corp 熱現像写真感光材料及び画像形成方法
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
CN102471248B (zh) 2009-08-10 2015-01-07 Bhi有限合伙公司 用于递送1,3-丙二磺酸的方法、化合物和组合物
CN105837553B (zh) 2011-07-08 2018-10-30 先正达参股股份有限公司 用于制备硫杂环丁胺的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140243312A1 (en) * 2013-02-22 2014-08-28 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives
WO2016024185A1 (en) * 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide(P F-04965842):A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases;MICHAEL L. VAZQUEZ ,ET AL;《JOURNAL OF MEDICINAL CHEMISTRY》;第61卷(第61期);表3,化合物25,合成图1,第1145页化合物25,第1147页化合物48b *

Also Published As

Publication number Publication date
KR20210029234A (ko) 2021-03-15
JP7437646B2 (ja) 2024-02-26
KR102568464B1 (ko) 2023-08-21
WO2020008391A1 (en) 2020-01-09
TW202017929A (zh) 2020-05-16
ES3045115T3 (en) 2025-11-27
CN112384282A (zh) 2021-02-19
EP3817810C0 (en) 2025-09-17
MX2023006842A (es) 2023-06-22
IL279926A (en) 2021-03-01
US20210009601A1 (en) 2021-01-14
MX2020013896A (es) 2021-03-09
TWI709562B (zh) 2020-11-11
US11254684B2 (en) 2022-02-22
BR112020025701A2 (pt) 2021-03-16
EP3817810A1 (en) 2021-05-12
JP2020007308A (ja) 2020-01-16
HRP20251339T1 (hr) 2025-12-19
US20220127274A1 (en) 2022-04-28
US20200123159A1 (en) 2020-04-23
AU2019299666B2 (en) 2024-07-11
ZA202100196B (en) 2022-09-28
AU2019299666A1 (en) 2021-01-07
IL279926B2 (en) 2023-12-01
US10815240B2 (en) 2020-10-27
IL279926B1 (en) 2023-08-01
CA3105161A1 (en) 2020-01-09
EP3817810B1 (en) 2025-09-17
US12018031B2 (en) 2024-06-25
CA3105161C (en) 2022-11-15

Similar Documents

Publication Publication Date Title
CA3105161C (en) Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof
US20250282789A1 (en) Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
RU2780482C2 (ru) СПОСОБ ПОЛУЧЕНИЯ И ПРОМЕЖУТОЧНЫЕ ПРОДУКТЫ ДЛЯ ПОЛУЧЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА И ЕГО ПРИМЕНЕНИЕ
HK40047992A (en) Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof
RU2803145C2 (ru) Кристаллический пиримидинил-3,8-диазабицикло[3.2.1]октанилметанон и его применение
HK40047992B (en) Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof
US12410172B2 (en) Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1H-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
HK40059389A (en) Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1] octanylmethanone compound and use thereof
HK40119391A (en) Pcsk9 inhibitors and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40047992

Country of ref document: HK

GR01 Patent grant